智飞生物：HK.3-JN.1新冠病毒mRNA疫苗获临床试验批准

Core Viewpoint - Zhifei Biological (300122.SZ) announced that its wholly-owned subsidiary, Anhui Zhifei Longkema Biological Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its self-developed HK.3-JN.1 mRNA vaccine for the prevention of diseases caused by novel coronavirus infection [1] Group 1 - The HK.3-JN.1 mRNA vaccine is designed to prevent diseases caused by novel coronavirus infection [1] - The approval allows the company to initiate clinical trials for the vaccine [1]